Piroxicam vs. Meloxicam: Long-Acting NSAID Comparison for PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Piroxicam (Feldene) and meloxicam (Mobic) are both long-acting NSAIDs in the oxicam class, but they differ in COX selectivity, half-life, and safety profile. Understanding why a physician chooses one over the other helps PI attorneys evaluate anti-inflammatory treatment decisions in pharmacy lien records.

Piroxicam (Feldene) and meloxicam (Mobic) are both oxicam-class NSAIDs with long half-lives that allow once-daily dosing, but meloxicam is preferentially COX-2 selective at lower doses while piroxicam is a non-selective COX inhibitor with a longer half-life and higher GI risk. In personal injury pharmacy records, both drugs signal chronic inflammatory pain requiring sustained anti-inflammatory therapy, but their different risk profiles affect prescribing decisions and case documentation.

• Meloxicam is the most commonly prescribed long-acting NSAID in PI cases due to its favorable GI safety profile at standard doses
• Piroxicam has an exceptionally long half-life (50 hours) providing extended anti-inflammatory coverage but with higher GI bleeding risk
• Both allow once-daily dosing, improving medication adherence during long PI treatment courses
• Neither is a controlled substance, but both require GI protection co-prescribing for extended use
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the clinical rationale for NSAID selection and any concurrent GI-protective therapy

Mechanism of Action

Meloxicam is an enolic acid (oxicam) derivative that inhibits cyclooxygenase (COX) enzymes. At standard therapeutic doses (7.5-15 mg daily), meloxicam demonstrates preferential COX-2 selectivity, meaning it more selectively inhibits the COX-2 isoenzyme responsible for inflammation and pain while relatively sparing COX-1, which maintains the protective gastric mucosal lining. This preferential selectivity diminishes at higher doses but provides a GI safety advantage at standard prescribing.

Piroxicam is also an oxicam derivative but is a non-selective COX inhibitor, blocking both COX-1 and COX-2 enzymes without preferential selectivity. It has an exceptionally long elimination half-life of approximately 50 hours (compared to meloxicam's 15-20 hours), which provides extended anti-inflammatory action but also means that adverse effects persist longer and the drug takes approximately 7-12 days to reach steady-state plasma concentrations.

Side-by-Side Comparison

Clinical Significance for Personal Injury

Meloxicam is one of the most frequently prescribed NSAIDs in PI pharmacy records. Its once-daily dosing, favorable GI profile at standard doses, and strong evidence base for musculoskeletal pain make it a natural choice for physicians managing chronic post-traumatic inflammation. Meloxicam commonly appears in cases involving ongoing joint pain, post-traumatic arthritis, chronic soft tissue inflammation, and as maintenance anti-inflammatory therapy during prolonged recovery periods.

Piroxicam in the pharmacy record is less common in modern PI practice but signals specific clinical reasoning. Its exceptionally long half-life provides sustained anti-inflammatory coverage that may be advantageous for patients with severe, constant inflammatory pain — conditions where even once-daily meloxicam does not provide adequate 24-hour coverage, or where the physician wants the most sustained anti-inflammatory effect available in an oral NSAID. Piroxicam is also available as a topical gel formulation in some markets, though the oral form is more common in US pharmacy records.

A transition from meloxicam to piroxicam documents that the treating physician determined a more aggressive anti-inflammatory approach was needed. Conversely, a transition from piroxicam to meloxicam may indicate the physician is prioritizing GI safety while maintaining long-acting NSAID coverage — a clinically sound decision for patients on extended NSAID therapy.

When Physicians Choose One Over the Other

Physicians select meloxicam when:

• Standard long-acting NSAID therapy is needed with once-daily convenience
• GI safety is a priority and preferential COX-2 selectivity provides a meaningful advantage
• The patient will be on NSAID therapy for weeks to months and minimizing GI risk is clinically important
• The physician follows current prescribing guidelines that favor meloxicam over older, non-selective NSAIDs

Physicians select piroxicam when:

• Maximum sustained anti-inflammatory coverage is needed for severe chronic inflammation
• The patient's inflammatory pain is not adequately controlled on meloxicam
• The physician wants the longest-acting oral NSAID available (50-hour half-life vs. 15-20 hours)
• Post-traumatic arthritis or severe joint inflammation requires aggressive anti-inflammatory therapy
• The injury involves significant inflammatory pathology (post-traumatic synovitis, bursitis, tendinitis) that has not responded to other NSAIDs

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When piroxicam appears in a PI pharmacy record, it tells us the physician needed the most sustained anti-inflammatory effect available. The 50-hour half-life means the drug is constantly working against inflammation — this is not a casual prescribing choice, and it documents significant ongoing inflammatory pathology from the injury."

GI Protection Co-Prescribing

Both meloxicam and piroxicam increase the risk of GI bleeding and ulceration, particularly with long-term use. Current clinical guidelines recommend concurrent GI-protective therapy — typically a proton pump inhibitor (omeprazole, pantoprazole) or an H2 blocker (famotidine) — when NSAIDs are prescribed for extended periods. The presence of a GI-protective agent alongside either NSAID in the pharmacy lien record demonstrates appropriate clinical monitoring and standard-of-care prescribing.

Piroxicam's non-selective COX inhibition and long half-life make GI protection particularly important. The FDA has specifically warned about piroxicam's GI risk, and its prescribing information carries a boxed warning regarding serious gastrointestinal events. Attorneys reviewing lien records should verify that GI-protective therapy was co-prescribed when piroxicam was used for extended periods.

For more on NSAID prescribing in PI cases, see Meloxicam vs. Naproxen Anti-Inflammatory Comparison. For information on piroxicam specifically, read Piroxicam (Feldene) as an Anti-Inflammatory in PI Cases.